Fisetin — Benefits Deep Dive

Fisetin is a flavonol found most abundantly in strawberries (~160 µg/g fresh weight), with smaller amounts in apples, persimmons, cucumbers, and onions. In 2018 a Mayo Clinic screen led by James Kirkland and Tamar Tchkonia identified fisetin as the most potent natural senolytic among ten flavonoids tested — a class of molecules that selectively eliminate senescent “zombie” cells that accumulate with age. The Yousefzadeh et al. EBioMedicine paper showed that fisetin in already-aged mice reduced senescent-cell burden across tissues, restored homeostasis, and extended both median and maximum lifespan. The AFFIRM-LITE trial and related senolytic studies are now running at Mayo Clinic in older adults. The four benefit pages below explore the senolytic mechanism, brain and cognitive applications, the broader anti-aging context, and the older-established anti-inflammatory and mast-cell-stabilizing literature — with honest framing throughout that the striking animal data still substantially outruns the human clinical evidence.

Deep-Dive Articles

Senolytic Activity

The Yousefzadeh 2018 EBioMedicine paper that identified fisetin as the most-potent natural senolytic among ten flavonoids screened, James Kirkland and Tamar Tchkonia's Mayo Clinic translational program, the AFFIRM-LITE trial, the dasatinib + quercetin (D+Q) cocktail context, the BCL-2/BCL-xL/BCL-W inhibition mechanism, and the honest framing that animal data is striking but human efficacy data remains preliminary.

Brain Health and Cognition

Pamela Maher's sustained work at the Salk Institute (2009, 2012, 2017) showing hippocampal protection, memory preservation in Alzheimer's transgenic mice, BDNF and glutathione mechanisms, and Sapozhnikov et al. 2018 demonstrating stroke recovery effects. The preclinical neuroprotective dossier is one of the strongest non-senolytic arguments for fisetin.

Anti-Aging

The broader “longevity flavonoid” framing — mitochondrial protection, Sestrin/AMPK signaling, Nrf2 antioxidant response, sirtuin activation, the strawberry/apple/persimmon dietary sources, and the dose discrepancy between dietary intake (~1-5 mg/day from typical diets) and supplemental research doses (100-1000 mg).

Inflammation and Allergy

The older-established literature: Park 2007 and Hendriks 2008 on NF-κB and cytokine suppression, mast-cell stabilization comparable to quercetin, atopic dermatitis pilot data, and the practical case for fisetin as a quercetin-class anti-allergic and anti-inflammatory flavonoid in everyday use independent of the senolytic story.

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why Fisetin Produces Effects Across So Many Systems
  3. Research Papers: Senolytic Activity
  4. Research Papers: Brain Health & Cognition
  5. Research Papers: Anti-Aging & Mitochondrial
  6. Research Papers: Inflammation & Allergy
  7. Research Papers: Pharmacology, Bioavailability, Safety
  8. External Authoritative Resources
  9. Connections

Why Fisetin Produces Effects Across So Many Systems

Fisetin is structurally a flavonol — the same chemical sub-family as quercetin and kaempferol — differing from quercetin by a single missing hydroxyl group on the B-ring. That tiny structural difference disproportionately changes both its biological selectivity and its membrane permeability, and the consequences explain why fisetin produces measurable effects across cellular senescence, neuronal survival, mitochondrial function, and inflammation — rather than fitting neatly into a single “antioxidant” bucket.

  1. Selective senescent-cell apoptosis via SCAP inhibition — senescent cells survive by over-expressing the anti-apoptotic proteins BCL-2, BCL-xL, BCL-W, and several PI3K/AKT survival nodes (collectively the “senescent-cell anti-apoptotic pathways” or SCAPs). Fisetin inhibits multiple SCAPs simultaneously, tipping already-stressed senescent cells into programmed cell death while sparing healthy cells (Yousefzadeh 2018). This is the mechanism behind the senolytic effect in aged mice and the foundational Mayo Clinic dossier.
  2. Mitochondrial protection and Sestrin/AMPK signaling — fisetin preserves mitochondrial membrane potential under oxidative stress and activates the energy-sensing AMP-activated protein kinase (AMPK) pathway, which in turn upregulates Sestrin family proteins, suppresses mTOR signaling, and triggers autophagy. The same broad set of metabolic effects underlies the “longevity flavonoid” framing and overlaps mechanistically with the established effects of metformin, rapamycin, and caloric restriction.
  3. Neurotrophic effects (BDNF, glutathione preservation, p25 inhibition) — fisetin uniquely upregulates brain-derived neurotrophic factor (BDNF) in hippocampal neurons, preserves intracellular glutathione (the brain's primary antioxidant), and inhibits the calpain-mediated cleavage of p35 to neurotoxic p25 (a tau-tangle driver in Alzheimer's disease). Pamela Maher's group at the Salk Institute has documented these effects across more than a decade of work that underlies the cognitive and stroke-recovery dossier.
  4. NF-κB and cytokine suppression, mast-cell stabilization — fisetin inhibits the master pro-inflammatory transcription factor NF-κB and stabilizes mast cells against IgE-triggered degranulation (Park 2007, Hendriks 2008). This is the older and clinically best-established arm of fisetin pharmacology — mechanistically nearly identical to quercetin but with somewhat better cell permeability — and is the basis for the anti-inflammatory and anti-allergic applications.
  5. Nrf2 activation — fisetin activates the Nrf2 transcription factor that drives expression of phase-II detoxification enzymes (NQO1, HO-1, glutamate-cysteine ligase) and the body's endogenous antioxidant defense. This effect is shared with sulforaphane (from broccoli sprouts) and with other polyphenols but contributes meaningfully to the cross-system effects.

The practical complication is bioavailability. Free fisetin has poor aqueous solubility and is extensively glucuronidated and sulfated on first-pass hepatic metabolism, with a plasma half-life of only ~1-3 hours. This is why most human studies use a pulsed “hit and run” regimen of high doses for 2-3 consecutive days rather than continuous low daily dosing — senescent cells take weeks to re-accumulate, so the short serum half-life is acceptable. Commercial formulations attempt to address absorption with liposomes, phytosome encapsulation (Novusetin), or co-administration with piperine, with mixed published evidence on actual plasma-level improvement.

The most consequential caveat is that the recommended “senolytic protocol” of 20 mg/kg body weight on two consecutive days per month is extrapolated from the mouse data, not validated by published human efficacy trials. The Mayo Clinic AFFIRM and AFFIRM-LITE trials are running precisely to test whether the mouse-translated dose produces the predicted effects on senescent-cell burden, frailty, and inflammatory cytokines in older humans. As of this writing the early biomarker data is encouraging but the larger trials needed to establish efficacy and dose-response are still in progress.

Back to Table of Contents

Research Papers: Senolytic Activity

  1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. — PubMed: Yousefzadeh 2018
  2. Zhu Y, Tchkonia T, Pirtskhalava T, et al. (2015). The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. — PubMed: Zhu & Tchkonia 2015
  3. Kirkland JL, Tchkonia T (2020). Senolytic drugs: from discovery to translation. Journal of Internal Medicine. — PubMed: Kirkland & Tchkonia 2020
  4. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. (2019). Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. — PubMed: Hickson D+Q 2019
  5. Justice JN, Nambiar AM, Tchkonia T, et al. (2019). Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. — PubMed: Justice IPF 2019
  6. Kirkland JL, Tchkonia T (2017). Cellular senescence: a translational perspective. EBioMedicine. — PubMed: Translational perspective 2017
  7. Mayo Clinic AFFIRM-LITE trial (fisetin in older adults) — PubMed: AFFIRM-LITE
  8. Baker DJ, Wijshake T, Tchkonia T, et al. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. — PubMed: Baker p16 clearance
  9. Xu M, Pirtskhalava T, Farr JN, et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nature Medicine. — PubMed: Xu 2018
  10. Senescent-cell anti-apoptotic pathways (SCAPs) and BCL-2 family inhibition — PubMed: SCAPs and BCL-2 family

Back to Table of Contents

Research Papers: Brain Health & Cognition

  1. Maher P (2009). Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes & Nutrition. — PubMed: Maher 2009
  2. Maher P, Akaishi T, Abe K (2006). Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. PNAS. — PubMed: Maher 2006 PNAS
  3. Currais A, Prior M, Dargusch R, et al. (2014). Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice. Aging Cell. — PubMed: Currais 2014
  4. Sapozhnikov L, et al. (2018). Fisetin and stroke recovery. — PubMed: Fisetin stroke recovery
  5. Maher P (2017). Protective effects of fisetin and other berry flavonoids in Parkinson's disease. Food & Function. — PubMed: Maher 2017 Parkinson's
  6. Prior M, Chiruta C, Currais A, et al. (2014). Back to the future with phenotypic screening. ACS Chemical Neuroscience. — PubMed: Prior 2014
  7. Fisetin and BDNF (brain-derived neurotrophic factor) expression — PubMed: Fisetin and BDNF
  8. Fisetin and tau hyperphosphorylation in Alzheimer's models — PubMed: Fisetin and tau
  9. Fisetin and glutathione preservation in neurons — PubMed: Fisetin glutathione neurons
  10. Fisetin and ischemic stroke rodent models — PubMed: Fisetin ischemic stroke models

Back to Table of Contents

Research Papers: Anti-Aging & Mitochondrial

  1. Khan N, Syed DN, Ahmad N, Mukhtar H (2013). Fisetin: a dietary antioxidant for health promotion. Antioxidants & Redox Signaling. — PubMed: Khan 2013 review
  2. Fisetin and mitochondrial membrane potential preservation — PubMed: Fisetin and mitochondria
  3. Fisetin, AMPK activation, and mTOR suppression — PubMed: Fisetin AMPK/mTOR
  4. Sestrin family proteins in longevity signaling — PubMed: Sestrin in longevity
  5. Fisetin and Nrf2 antioxidant response element activation — PubMed: Fisetin Nrf2
  6. Fisetin and SIRT1 activation — PubMed: Fisetin and SIRT1
  7. Dietary flavonoid intake and all-cause mortality cohort studies — PubMed: Flavonoid intake mortality
  8. Strawberry consumption and flavonoid intake epidemiology — PubMed: Strawberry flavonoid intake
  9. Polyphenol intake estimation in Western diets (Phenol-Explorer) — PubMed: Polyphenol intake estimation
  10. Fisetin in C. elegans lifespan extension — PubMed: Fisetin in C. elegans

Back to Table of Contents

Research Papers: Inflammation & Allergy

  1. Park HH, Lee S, Son HY, et al. (2007). Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Archives of Pharmacal Research. — PubMed: Park 2007
  2. Hendriks JJA, et al. (2008). Fisetin and NF-κB / cytokine suppression. — PubMed: Hendriks 2008
  3. Fisetin and atopic dermatitis pilot data — PubMed: Fisetin and atopic dermatitis
  4. Quercetin and fisetin comparative mast-cell stabilization — PubMed: Quercetin vs fisetin mast cells
  5. Fisetin and inhibition of TNF-α-induced inflammation — PubMed: Fisetin and TNF-α
  6. Fisetin and inhibition of inducible COX-2 expression — PubMed: Fisetin and COX-2
  7. Fisetin and reduction of IL-6 and IL-8 in inflammatory states — PubMed: Fisetin and IL-6/IL-8
  8. Fisetin and asthma / airway inflammation models — PubMed: Fisetin and asthma models
  9. Fisetin and inflammatory bowel disease animal models — PubMed: Fisetin and IBD models
  10. Senescence-associated secretory phenotype (SASP) cytokine profile — PubMed: SASP cytokine profile

Back to Table of Contents

Research Papers: Pharmacology, Bioavailability, Safety

  1. Fisetin pharmacokinetics in rodents and humans — PubMed: Fisetin pharmacokinetics
  2. Fisetin glucuronidation and sulfation phase-II metabolism — PubMed: Fisetin metabolism
  3. Novusetin / phytosome fisetin formulation studies — PubMed: Novusetin formulation
  4. Fisetin liposomal encapsulation absorption studies — PubMed: Fisetin liposomal
  5. Fisetin safety and toxicology preclinical studies — PubMed: Fisetin safety
  6. Fisetin antiplatelet activity and bleeding risk — PubMed: Fisetin antiplatelet
  7. Flavonoid-drug interactions and cytochrome P450 inhibition — PubMed: Flavonoid CYP interactions
  8. Phenol-Explorer database fisetin content of common foods — PubMed: Phenol-Explorer fisetin
  9. Senolytic dosing translation from mouse to human — PubMed: Senolytic dose translation
  10. Pulsed (intermittent) vs continuous senolytic dosing rationale — PubMed: Pulsed senolytic dosing

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents